Abstract 511: Nitric Oxide Attenuates Matrix Metalloproteinase-9 Production by Endothelial Cells

Abstract only Impaired nitric oxide (NO) bioavailability and imbalanced matrix metalloproteinase (MMP) activity are key pathogenetic mechanisms involved in cardiovascular diseases. However, there is little evidence supporting a direct link between these mechanisms, although NO is known to interfere...

Full description

Saved in:
Bibliographic Details
Published inHypertension (Dallas, Tex. 1979) Vol. 60; no. suppl_1
Main Authors Meschiari, Cesar A, Izidoro-Toledo, Tatiane C, Gerlach, Raquel F, Tanus-Santos, José
Format Journal Article
LanguageEnglish
Published 01.09.2012
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract only Impaired nitric oxide (NO) bioavailability and imbalanced matrix metalloproteinase (MMP) activity are key pathogenetic mechanisms involved in cardiovascular diseases. However, there is little evidence supporting a direct link between these mechanisms, although NO is known to interfere with nuclear factor kappa B (NFB) activity, an important modulator of MMP-9 expression. Moreover, it is not known whether the possible effects of NO on MMPs is dependent on cyclic GMP formation. Objective: We examined the effect of NO donors on MMP-9 production by endothelial cells, and if this effect is dependent on cGMP formation or NFB activation. Methods: Human umbilical vein endothelial cells were cultured in appropriate medium and treated for 24 hours with 10 nM phorbol myristate acetate (PMA; a MMP-9 inducer) and other drugs: NO donors (S-nitroso-N-acetylpenicillamine; SNAP, or DetaNONOate), 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; a soluble guanylyl cyclase inhibitor), BAY 11-7082 (a NFB inhibitor), or their vehicles. Conditioned media were analyzed by gelatin zimography. Results: PMA increased MMP-9 activity from 0.10±0.08 arbitrary units (AU) to 0.94±0.18 AU ( P< 0.05). Treatment with SNAP (200 or 320 μM) attenuated the increases in MMP-9 activity induced by PMA (0.52±0.16 AU or 0.25±0.10 AU, respectively; both P< 0.05 vs. PMA). DetaNONOate (320 or 400 μM) exerted similar inhibitory effects on MMP-9 activity (0.57±0.13 AU and 0.45±0.06 AU, respectively; both P< 0.05 vs. PMA). Conversely, treatment with ODQ (10 or 32 μM) had no effects on 200 μM SNAP-induced inhibition of PMA-stimulated MMP-9 activity (0.25±020 AU and 0.14±0.11 AU, respectively; both P< 0.05 vs. PMA). Nevertheless, 3.2 and 5 μM BAY 11-7082 decreased PMA-stimulated MMP-9 activity (0.54±0.07 AU and 0.27±0.09 AU, respectively; both P< 0.05 vs. PMA). Conclusion: Our results suggest that NO attenuates MMP-9 production by endothelial cells in a concentration-dependent manner. While this effect is independent of soluble guanylate cyclase activation, it apparently involves inhibition of NFB activity.
ISSN:0194-911X
1524-4563
DOI:10.1161/hyp.60.suppl_1.A511